RIM: Analysts' Upgrades, Downgrades

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK (TheStreet) -- CHANGE IN RATINGS

AK Steel (AKS) downgraded at Goldman from Buy to Neutral. Company is facing higher input costs.

The Buckle (BKE) upgraded at Goldman from Sell to Neutral. $28 price target. Fashion cycle is easing for the company.

Corrections Corp of America (CXW) downgraded at Barclays to Equal Weight from Overweight. Minimal margin improvement opportunities. Price target raised by a dollar to $28.

Ruddick (RDK) downgraded at BMO from Outperform to Market Perform. Valuation call, based on a $38 price target.

Research in Motion (RIMM) downgraded at Kaufman from Buy to Hold. $60 price target. Company is facing increased competition.

Rovi (ROVI) rated new Outperform at BMO. Coverage of ROVI was started with an Outperform rating. $60 price target. Growth should accelerate as its content and reach expands.

Reliance Steel (RS) upgraded at Goldman from Neutral to Buy. Company has exposure to growth in the aerospace and energy markets.

Seattle Genetics (SGEN) rated new Overweight at Piper Jaffray. $20 price target. Company is on the verge of bringing its first drug to market.

Symantec (SYMC) upgraded at ISI from Hold to Buy. $22 price target. Company is executing better and is a potential takeover target.

Taleo (TLEO) downgraded at Credit Suisse to Neutral from Outperform. Valuation call. Maintain $30 price target.

Trinity Industries (TRN) rated new Outperform at Wells Fargo. Rail supply industry appears to be at the beginning of a multi-year recovery.

Viropharma (VPHM) rated new Overweight at Piper Jaffray. $20 price target. HAE drug should ultimately be able to generate $500 million of annual U.S. sales.

This article was written by a staff member of TheStreet.